Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company's products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of functions of the sexual system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions. It also trades in food supplements; provides secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; and purchases, collects, grows, produces, and trades in herbs and medicinal plants. In addition, the company engages in the retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Further, it offers market and public opinion research services; and engages in non-pharma activities, such as veterinary vaccines, infusion solutions. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.
Sopharma AD Dividend Announcement
• Sopharma AD announced a semi annually dividend of zł0.17 per ordinary share which will be made payable on 2024-12-23. Ex dividend date: 2024-11-07
• Sopharma AD annual dividend for 2024 was zł0.36
• Sopharma AD annual dividend for 2023 was zł3.36
• Sopharma AD's trailing twelve-month (TTM) dividend yield is 17.39%
• Sopharma AD's payout ratio for the trailing twelve months (TTM) is 271.30%
Sopharma AD Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-11-07 | zł0.17 | semi annually | 2024-12-23 |
2024-07-11 | zł0.20 | semi annually | 2024-08-26 |
2023-12-07 | zł1.99 | semi annually | 2024-01-22 |
2023-06-15 | zł1.37 | semi annually | 2023-07-31 |
2020-10-08 | zł0.09 | semi annually | 2020-11-23 |
2020-06-18 | zł0.16 | semi annually | 2020-08-03 |
2019-12-23 | zł0.11 | semi annually | 2020-01-22 |
2018-09-27 | zł0.11 | semi annually | 2018-10-22 |
2018-06-28 | zł0.25 | semi annually | 2018-07-23 |
2017-06-15 | zł0.22 | semi annually | 2017-07-24 |
2016-06-30 | zł0.07 | semi annually | |
2014-07-03 | zł0.07 | semi annually | |
2013-07-04 | zł0.07 | semi annually | |
2012-07-02 | zł0.07 | semi annually |
Sopharma AD Dividend per year
Sopharma AD Dividend growth
Sopharma AD Dividend Yield
Sopharma AD current trailing twelve-month (TTM) dividend yield is 17.39%. Interested in purchasing Sopharma AD stock? Use our calculator to estimate your expected dividend yield:
Sopharma AD Financial Ratios
Sopharma AD Dividend FAQ
Other factors to consider when evaluating Sopharma AD as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Sopharma AD stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Sopharma AD's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Sopharma AD publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Sopharma AD distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Sopharma AD are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Sopharma AD sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Sopharma AD distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Sopharma AD declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Sopharma AD's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Sopharma AD's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.